- Home
- RNXT vs ANVS Comparison
RNXT vs ANVS Comparison
Compare RNXT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- ANVS
- Stock Information
- Founded
- RNXT 2012
- ANVS 2008
- Country
- RNXT United States
- ANVS United States
- Employees
- RNXT N/A
- ANVS N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- ANVS Health Care
- Exchange
- RNXT Nasdaq
- ANVS Nasdaq
- Market Cap
- RNXT N/A
- ANVS 31.2M
- IPO Year
- RNXT 2021
- ANVS 2020
- Fundamental
- Price
- RNXT $0.80
- ANVS $1.13
- Analyst Decision
- RNXT Strong Buy
- ANVS Strong Buy
- Analyst Count
- RNXT 2
- ANVS 5
- Target Price
- RNXT $6.00
- ANVS $37.00
- AVG Volume (30 Days)
- RNXT 89.8K
- ANVS 259.6K
- Earning Date
- RNXT 05-09-2025
- ANVS 05-12-2025
- Dividend Yield
- RNXT N/A
- ANVS N/A
- EPS Growth
- RNXT N/A
- ANVS N/A
- EPS
- RNXT N/A
- ANVS N/A
- Revenue
- RNXT $43,000.00
- ANVS N/A
- Revenue This Year
- RNXT $690.69
- ANVS N/A
- Revenue Next Year
- RNXT $4,006.81
- ANVS N/A
- P/E Ratio
- RNXT N/A
- ANVS N/A
- Revenue Growth
- RNXT N/A
- ANVS N/A
- 52 Week Low
- RNXT $0.75
- ANVS $1.11
- 52 Week High
- RNXT $1.69
- ANVS $20.00
- Technical
- Relative Strength Index (RSI)
- RNXT 31.82
- ANVS 25.79
- Support Level
- RNXT $0.75
- ANVS $1.16
- Resistance Level
- RNXT $1.01
- ANVS $2.07
- Average True Range (ATR)
- RNXT 0.09
- ANVS 0.15
- MACD
- RNXT -0.02
- ANVS -0.01
- Stochastic Oscillator
- RNXT 14.37
- ANVS 2.09
Stock Price Comparison Chart: RNXT vs ANVS
■ RNXT
■ ANVS
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.